{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.1G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "1"
          },
          "Protein Change": {
            "ref": "M",
            "alt": "N",
            "position": "1"
          },
          "Description in input context": "c.1G>A (p.M1N)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005264"
  },
  "Experiment Method": [
    {
      "Assay Method": "Inhibition of macroautophagy/proteasome degradation",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "PC12/TetOn cells",
        "Description": "PC12/Tet-On cells were used to study the effects of macroautophagy and proteasome inhibition on alpha-synuclein degradation."
      },
      "Readout type": "Qualitative/Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.1G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Inhibition of macroautophagy led to increased aggregation of alpha-synuclein in cells expressing the A30P variant."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Number of biological replicates not explicitly mentioned in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Number of technical replicates not explicitly mentioned in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type alpha-synuclein was used as a positive control for protein degradation assays."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector or vehicle treatment was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Not explicitly mentioned."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Protein degradation efficiency greater than 80% under control conditions.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Protein degradation efficiency less than 50% in the presence of inhibitors or pathogenic variants.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes",
        "Description": "These methods are commonly used to study protein degradation and aggregation in neurodegenerative diseases."
      }
    }
  ]
}